⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL27638250 | 0.78 | KDM4E (0.36) | — | |
| SCHEMBL13729992 | 0.75 | DPYD (0.39) | — | |
| SCHEMBL7099906 | 0.74 | — | — | |
| SCHEMBL275888 | 0.74 | — | — | |
| SCHEMBL4911972 | 0.73 | KIF11 (0.47) | — | |
| SCHEMBL24035534 | 0.72 | — | — | |
| SCHEMBL4397408 | 0.72 | — | — | |
| SCHEMBL17399885 | 0.72 | — | — | |
| SCHEMBL5173532 | 0.72 | — | — | |
| SCHEMBL194992 | 0.72 | KIF11 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835619-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | claimed |
| CN-118239947-A | Compound, intermediate, preparation method, pharmaceutical composition and application | 上海艾力斯医药科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114835619-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| WO-2020237025-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| CN-109970708-A | Cannibinoid receptor modulators | 艾尼纳制药公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-103492369-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2019-03-29 | — | — | CN | disclosed |
| EP-3091006-B1 | SULFONYLATION PROCESS USING NONAFLUOROBUTANESULFONYL FLUORIDE | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-17 | — | — | EP | disclosed |
| EP-3241826-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-3208269-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-3091006-A1 | SULFONYLATION PROCESS USING NONAFLUOROBUTANESULFONYL FLUORIDE | Janssen Pharmaceutica N.V. (BE) | 2016-11-09 | — | — | EP | disclosed |
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8481564-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-09 | — | — | US | disclosed |
| EP-2021335-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| WO-2011050160-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |